Activin A in Nonalcoholic Fatty Liver Disease

Vitamins and Hormones

Volumn 85, Issue , 2011, Pages 323-342

  Yndestad, Arne ^a   Haukeland, John Willy ^b   Dahl, Tuva B ^a   Halvorsen, Bente ^a,c   Aukrust, Pål ^a,c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Activin A; Liver; NAFLD; Steatohepatitis; Steatosis; TGF beta

Indexed keywords

ACTIVIN; ACTIVIN A;

ANIMAL; BOOK; FATTY LIVER; HUMAN; METABOLISM;

ACTIVINS; ANIMALS; FATTY LIVER; HUMANS;

EID: 79951877209     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385961-7.00015-9     Document Type: Book

References (89)

1. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005, 42(1):132-138.
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346(16):1221-1231.
3. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115(2):209-218.
4. Beier K., Volkl A., Fahimi H.D. Suppression of peroxisomal lipid beta-oxidation enzymes of TNF-alpha. FEBS Lett. 1992, 310(3):273-276.
5. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132(2):112-117.
6. Bjornsson E., Angulo P. Non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2007, 42(9):1023-1030.
7. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114(2):147-152.
8. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
9. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-140.
10. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms. Diabetologia 2005, 48(4):634-642.
11. Canbay A., Taimr P., Torok N., Higuchi H., Friedman S., Gores G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 2003, 83(5):655-663.
12. Cerami A., Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol. Today 1988, 9(1):28-31.
13. Chen Y.G., Lui H.M., Lin S.L., Lee J.M., Ying S.Y. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. (Maywood) 2002, 227(2):75-87.
14. Cortez-Pinto H., de Moura M.C., Day C.P. Non-alcoholic steatohepatitis: From cell biology to clinical practice. J. Hepatol. 2006, 44(1):197-208.
15. Dam-Larsen S., Franzmann M., Andersen I.B., Christoffersen P., Jensen L.B., Sorensen T.I., Becker U., Bendtsen F. Long term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 2004, 53(5):750-755.
16. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111(11):1448-1454.
17. Day C. Metabolic syndrome, or what you will: Definitions and epidemiology. Diab. Vasc. Dis. Res. 2007, 4(1):32-38.
18. Day C.P., James O.F. Steatohepatitis: A tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
19. De Bleser P.J., Niki T., Xu G., Rogiers V., Geerts A. Localization and cellular sources of activins in normal and fibrotic rat liver. Hepatology 1997, 26(4):905-912.
20. de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 2004, 15(1):1-11.
21. Deli A., Kreidl E., Santifaller S., Trotter B., Seir K., Berger W., Schulte-Hermann R., Rodgarkia-Dara C., Grusch M. Activins and activin antagonists in hepatocellular carcinoma. World J. Gastroenterol. 2008, 14(11):1699-1709.
22. den Boer M.A., Voshol P.J., Schroder-van der Elst J.P., Korsheninnikova E., Ouwens D.M., Kuipers F., Havekes L.M., Romijn J.A. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 2006, 147(10):4553-4558.
23. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: Role of insulin resistance. Gut 2004, 53(7):1020-1023.
24. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115(5):1343-1351.
25. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
26. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998, 101(4):890-898.
27. Fassio E., Alvarez E., Dominguez N., Landeira G., Longo C. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004, 40(4):820-826.
28. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102(1):42-47.
29. Fromenty B., Robin M.A., Igoudjil A., Mansouri A., Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004, 30(2):121-138.
30. Furukawa M., Nobusawa R., Shibata H., Eto Y., Kojima I. Initiation of insulin secretion in glucose-free medium by activin A. Mol. Cell. Endocrinol. 1995, 113(1):83-87.
31. Gold E.J., Francis R.J., Zimmermann A., Mellor S.L., Cranfield M., Risbridger G.P., Groome N.P., Wheatley A.M., Fleming J.S. Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis. Mol. Cell. Endocrinol. 2003, 201(1-2):143-153.
32. Gressner A.M., Lahme B., Mannherz H.G., Polzar B. TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J. Hepatol. 1997, 26(5):1079-1092.
33. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Weiskirchen R., Gressner A.M. Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. Liver Int. 2008, 28(9):1207-1216.
34. Grusch M., Drucker C., Peter-Vorosmarty B., Erlach N., Lackner A., Losert A., Macheiner D., Schneider W.J., Hermann M., Groome N.P., et al. Deregulation of the activin/follistatin system in hepatocarcinogenesis. J. Hepatol. 2006, 45(5):673-680.
35. Gupte P., Amarapurkar D., Agal S., Baijal R., Kulshrestha P., Pramanik S., Patel N., Madan A., Amarapurkar A., Hafeezunnisa Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 2004, 19(8):854-858.
36. Han Y.P. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S88-S91.
37. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am. J. Gastroenterol. 2003, 98(9):2042-2047.
38. Haukeland J.W., Damas J.K., Konopski Z., Loberg E.M., Haaland T., Goverud I., Torjesen P.A., Birkeland K., Bjoro K., Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44(6):1167-1174.
39. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109(9):1125-1131.
40. Hube F., Hauner H. The role of TNF-alpha in human adipose tissue: Prevention of weight gain at the expense of insulin resistance?. Horm. Metab. Res. 1999, 31(12):626-631.
41. Hubner G., Alzheimer C., Werner S. Activin: A novel player in tissue repair processes. Histol. Histopathol. 1999, 14(1):295-304.
42. Hughes R.D., Evans L.W. Activin A and follistatin in acute liver failure. Eur. J. Gastroenterol. Hepatol. 2003, 15(2):127-131.
43. Iredale J.P. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 2007, 117(3):539-548.
44. Jones K.L., de Kretser D.M., Patella S., Phillips D.J. Activin A and follistatin in systemic inflammation. Mol. Cell. Endocrinol. 2004, 225(1-2):119-125.
45. Jou J., Choi S.S., Diehl A.M. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28(4):370-379.
46. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116(6):1494-1505.
47. Kerner J., Hoppel C. Fatty acid import into mitochondria. Biochim. Biophys. Acta 2000, 1486(1):1-17.
48. Larter C.Z., Yeh M.M., Haigh W.G., Williams J., Brown S., Bell-Anderson K.S., Lee S.P., Farrell G.C. Hepatic free fatty acids accumulate in experimental steatohepatitis: Role of adaptive pathways. J. Hepatol. 2008, 48(4):638-647.
49. Lee J.Y., Kim K.M., Lee S.G., Yu E., Lim Y.S., Lee H.C., Chung Y.H., Lee Y.S., Suh D.J. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J. Hepatol. 2007, 47(2):239-244.
50. Lewis J.R., Mohanty S.R. Nonalcoholic fatty liver disease: A review and update. Dig. Dis. Sci. 2010, 55(3):560-578.
51. Li L., Yi Z., Seno M., Kojima I. Activin A and betacellulin: Effect on regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats. Diabetes 2004, 53(3):608-615.
52. Lin S.D., Kawakami T., Ushio A., Sato A., Sato S., Iwai M., Endo R., Takikawa Y., Suzuki K. Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure. J. Gastroenterol. Hepatol. 2006, 21(2):374-380.
53. Lind P. Interdependence of hepatic lipid and glucose metabolism: Novel pharmacological targets for diabetes. Curr. Opin. Investig. Drugs 2004, 5(4):395-401.
54. Ling N., Ying S.Y., Ueno N., Shimasaki S., Esch F., Hotta M., Guillemin R. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 1986, 321(6072):779-782.
55. Loria P., Lonardo A., Carulli N. Should nonalcoholic fatty liver disease be renamed?. Dig. Dis. 2005, 23(1):72-82.
56. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55(7):434-438.
57. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 2006, 45(4):600-606.
58. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
59. Mukherjee A., Sidis Y., Mahan A., Raher M.J., Xia Y., Rosen E.D., Bloch K.D., Thomas M.K., Schneyer A.L. FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc. Natl. Acad. Sci. USA 2007, 104(4):1348-1353.
60. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., Cassader M., David E., Cavallo-Perin P., Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002, 35(2):367-372.
61. Pangas S.A., Woodruff T.K. Activin signal transduction pathways. Trends Endocrinol. Metab. 2000, 11(8):309-314.
62. Patella S., Phillips D.J., de Kretser D.M., Evans L.W., Groome N.P., Sievert W. Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis. J. Hepatol. 2001, 34(4):576-583.
63. Patella S., Phillips D.J., Tchongue J., de Kretser D.M., Sievert W. Follistatin attenuates early liver fibrosis: Effects on hepatic stellate cell activation and hepatocyte apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290(1):G137-G144.
64. Piek E., Heldin C.H., Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 1999, 13(15):2105-2124.
65. Rodgarkia-Dara C., Vejda S., Erlach N., Losert A., Bursch W., Berger W., Schulte-Hermann R., Grusch M. The activin axis in liver biology and disease. Mutat. Res. 2006, 613(2-3):123-137.
66. Russell C.E., Hedger M.P., Brauman J.N., de Kretser D.M., Phillips D.J. Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2. Mol. Cell. Endocrinol. 1999, 148(1-2):129-136.
67. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120(5):1183-1192.
68. Schwall R.H., Robbins K., Jardieu P., Chang L., Lai C., Terrell T.G. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 1993, 18(2):347-356.
69. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002, 37(1):56-62.
70. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., Halavaara J., Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 2002, 87(7):3023-3028.
71. Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 2000, 6(1):77-86.
72. Smith C., Yndestad A., Halvorsen B., Ueland T., Waehre T., Otterdal K., Scholz H., Endresen K., Gullestad L., Froland S.S., et al. Potential anti-inflammatory role of activin A in acute coronary syndromes. J. Am. Coll. Cardiol. 2004, 44(2):369-375.
73. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008, 42(4):413-418.
74. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995, 22(6):1714-1719.
75. Tilg H., Moschen A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 2008, 19(10):371-379.
76. Ueda Y. Activin A increases Pax4 gene expression in pancreatic beta cell lines. FEBS Lett. 2000, 480(2-3):101-105.
77. Unger R.H., Orci L. Lipoapoptosis: Its mechanism and its diseases. Biochim. Biophys. Acta 2002, 1585(2-3):202-212.
78. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389(6651):610-614.
79. Wang M., Liu A., Garcia F.U., Rhim J.S., Stearns M.E. Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. Int. J. Oncol. 1999, 14(6):1185-1195.
80. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
81. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116(1):115-124.
82. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115(5):1111-1119.
83. Werner S., Alzheimer C. Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev. 2006, 17(3):157-171.
84. Yamaoka T., Idehara C., Yano M., Matsushita T., Yamada T., Ii S., Moritani M., Hata J., Sugino H., Noji S., et al. Hypoplasia of pancreatic islets in transgenic mice expressing activin receptor mutants. J. Clin. Invest. 1998, 102(2):294-301.
85. Yeh M.M., Brunt E.M. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 2007, 128(5):837-847.
86. Yndestad A., Ueland T., Øie E., Florholmen G., Halvorsen B., Attramadal H., Simonsen S., Frøland S.S., Gullestad L., Christensen G., et al. Elevated levels of activin A in heart failure: Potential role in myocardial remodeling. Circulation 2004, 109(11):1379-1385.
87. Yndestad A., Haukeland J.W., Dahl T.B., Bjoro K., Gladhaug I.P., Berge C., Damas J.K., Haaland T., Loberg E.M., Linnestad P., et al. A complex role of activin A in non-alcoholic fatty liver disease. Am. J. Gastroenterol. 2009, 104(9):2196-2205.
88. Yuen M.F., Norris S., Evans L.W., Langley P.G., Hughes R.D. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand. J. Gastroenterol. 2002, 37(2):233-238.
89. Zelman S. The liver in obesity. AMA Arch. Intern. Med. 1952, 90(2):141-156.